HIV and viral hepatitis coinfections: Advances and challenges

Gut

Volumn 61, Issue SUPPL. 1, 2012, Pages

  Lacombe, Karine ^a   Rockstroh, Juergen ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; CYCLOSPORIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS TENOFOVIR; EMTRICITABINE; IMMUNOGLOBULIN; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RALTEGRAVIR; RALTEGRAVIR PLUS RITONAVIR; RIBAVIRIN; RITONAVIR; SORAFENIB; TACROLIMUS; TELAPREVIR; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMORBIDITY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; DNA REPLICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; INFECTION CONTROL; INFECTION RISK; LIFE EXPECTANCY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; METABOLIC DISORDER; MIXED INFECTION; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; TREATMENT INDICATION; VERTICAL TRANSMISSION; VIRAL CONTAMINATION; VIREMIA; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS;

EID: 84860334991     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302062     Document Type: Review

References (118)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44(Suppl 1):S6-9. (Pubitemid 43053865)
2. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005;19:593-601. (Pubitemid 40543982)
3. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev 2007;9:25-39. (Pubitemid 46730281)
4. Soriano V, Mocroft A, Peters L, et al. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother 2010;65:548-55.
5. Nunez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005;5:374-82. (Pubitemid 40779258)
6. Shepard CW, Simard EP, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006;28:112-25. (Pubitemid 44289094)
7. Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect Dis 2004;4:437-44. (Pubitemid 38844128)
8. Soriano V, Mocroft A, Rockstroh J, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008;198:1337-44.
9. Rockstroh JK, Mocroft A, Soriano V, et al; EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992-1002. (Pubitemid 41266795)
10. Weinbaum CM, Sabin KM, Santibanez SS. Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS 2005;19(Suppl 3):S41-6. (Pubitemid 41682168)
11. Singal AK, Anand BS. Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol 2009;15:3713-24.
12. Qian HZ, Vermund SH, Kaslow RA, et al. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS 2006;20:1429-35. (Pubitemid 43948250)
13. Stabinski L, Reynolds SJ, Ocama P, et al. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther 2011;16:405-11.
14. Ghosn J, Pierre-Francois S, Thibault V, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 2004;5:303-6. (Pubitemid 39077124)
15. Gotz HM, van Doornum G, Niesters HG, et al. A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications. AIDS 2005;19:969-74. (Pubitemid 40834941)
16. Vogel M, Deterding K, Wiegand J, et al German Hepatitis Group; Hep-Net. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals - experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis 2009;49:317-19.
17. Bevilacqua E, Fabris A, Floreano P, et al. Genetic factors in mother-to-child transmission of HCV infection. Virology 2009;390:64-70.
18. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995;345:289-91.
19. Ngo-Giang-Huong N, Jourdain G, Sirirungsi W, et al. Human immunodeficiency virus - hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand. Int J Infect Dis 2010;14:e602-7.
20. Medrano J, Resino S, Vispo E, et al. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. J Viral Hepat 2011;18:325-30.
21. Zhou YH, Liu FL, Yao ZH, et al. Comparison of HIV-, HBV-, HCV- and co-infection prevalence between Chinese and Burmese intravenous drug users of the China - Myanmar border region. PLoS One 2011;6:e16349.
22. Maida I, Rios MJ, Perez-Saleme L, et al. Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era. AIDS Res Hum Retroviruses 2008;24:679-83. (Pubitemid 351748776)
23. Morsica G, Bagaglio S, Cicconi P, et al; Hepa I.C.o.N.A the Icona Foundation Study Groups. Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr 2009;51:574-81.
24. Boyd A, Lacombe K, Miailhes P, et al. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 2010;17:65-76.
25. Joshi D, O'Grady J, Dieterich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet 2011;377:1198-209.
26. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-13. (Pubitemid 37468321)
27. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006;44:47-55. (Pubitemid 41772515)
28. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009;48:1763-71.
29. Chun HM, Roediger MP, Hullsiek KH, et al Infectious Disease Clinical Research Program HIV Working Group. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012;205:185-93.
30. Dore GJ, Soriano V, Rockstroh J, et al; SMART INSIGHT study group. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 2010;24:857-65.
31. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007;196:670-6. (Pubitemid 47293847)
32. Babu CK, Suwansrinon K, Bren GD, et al. HIV induces TRAIL sensitivity in hepatocytes. PLoS One 2009;4:e4623.
33. Tuyama AC, Hong F, Saiman Y, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010;52:612-22.
34. Thibault S, Fromentin R, Tardif MR, et al. TLR2 and TLR4 triggering exerts contrasting effects with regard to HIV-1 infection of human dendritic cells and subsequent virus transfer to CD4+ T cells. Retrovirology 2009;6:42.
35. Wu J, Meng Z, Jiang M, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49:1132-40.
36. Katsounas A, Trippler M, Kottilil S, et al. Altered expression of SHIP, a Toll-like receptor pathway inhibitor, is associated with the severity of liver fibrosis in chronic hepatitis C virus infection. J Infect Dis 2011;204:1181-5.
37. Launay O, van der Vliet D, Rosenberg AR, et al; ANRS HB03 VIHVAC-B Trial. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011;305:1432-40.
38. Piroth L, Sene D, Pol S, et al. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 2007;21:1323-31. (Pubitemid 46883487)
39. Piroth L, Pol S, Lacombe K, et al GERMIVIC Study Group. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 2010;53:1006-12.
40. de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010;139:1934-41.
41. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008;48:590-8.
42. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-40.
43. Psevdos G Jr, Kim JH, Suh JS, et al. Predictors of loss of hepatitis B surface antigen in HIV-infected patients. World J Gastroenterol 2010;16:1093-6.
44. Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007;45:624-32. (Pubitemid 47328645)
45. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6. (Pubitemid 35472132)
46. Wendum D, Lacombe K, Chevallier M, et al. Histological scoring of fibrosis and activity in HIV-chronic hepatitis B related liver disease: performance of the METAVIR score assessed on virtual slides. J Clin Pathol 2009;62:361-3.
47. Ingiliz P, Valantin MA, Duvivier C, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009;49:436-42.
48. Mallet VO, Varthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009;23:1511-18.
49. Don CR, Stephen HC, Zachary DG, et al. Liver biopsy. J Hepatol 2009;49:1017-44.
50. Miailhes P, Pradat P, Chevallier M, et al. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients. J Viral Hepat 2011;18:61-9.
51. Bottero J, Lacombe K, Guechot J, et al. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. J Hepatol 2009;50:1074-83.
52. Cacoub P, Carrat F, Bedossa P, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study - ANRS HC02. J Hepatol 2008;48:765-73.
53. Sanchez-Conde M, Montes-Ramirez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010;17:280-6.
54. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189:1185-92. (Pubitemid 38457242)
55. Schildgen O, Schewe CK, Vogel M, et al. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 2004;18:2325-7. (Pubitemid 39620226)
56. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6. (Pubitemid 29510871)
57. Bonacini M, Kurz A, Locarnini S, et al. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002;122:244-5. (Pubitemid 34049213)
58. Bellini C, Keiser O, Chave JP, et al Swiss HIV Cohort Study. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med 2009;10:12-18.
59. Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123:1812-22. (Pubitemid 35408305)
60. Ingiliz P, Valantin MA, Thibault V, et al. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir Ther 2008;13:895-900.
61. Johnson RM, Ristig MB, Overton ET, et al. Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals. HIV Clin Trials 2007;8:173-81. (Pubitemid 47121762)
62. Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006;44:62-7. (Pubitemid 41772517)
63. Lacombe K, Ollivet A, Gozlan J, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006;20:2229-31. (Pubitemid 44684715)
64. Lacombe K, Gozlan J, Boyd A, et al. Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients. Antivir Ther 2008;13:705-13.
65. Peters MG, Andersen J, Lynch P, et al; ACTG Protocol A5127 Team. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: aCTG A5127. Hepatology 2006;44:1110-16. (Pubitemid 44748362)
66. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007;356:2614-21. (Pubitemid 46961006)
67. Sasadeusz J, Audsley J, Mijch A, et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 2008;22:947-55. (Pubitemid 351652245)
68. Low E, Cox A, Atkins M, et al. Telbivudine has activity against HIV-1. AIDS 2009;23:546-7.
69. Lin K, Karwowska S, Lam E, et al. Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. Antimicrob Agents Chemother 2010;54:2670-3.
70. Chen Y, Li X, Ye B, et al. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res 2011;91:23-31.
71. European Aids Clinical Society. Guidelines Version 6-October 2011. http://www.europeanaidsclinicalsociety.org/index.php?option=com- content&view=article&id=59&Itemid=41 (date accessed 14 Mar 2012).
72. Lacombe K, Gozlan J, Boyd A, et al. Hepatitis B virus blippers and rebounders under treatment with tenofovir in HIV-HBV coinfection. The Conference on Retroviruses and Opportunistic Infections; 8-11 February 2006, Montreal, Canada, 2009.
73. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, et al. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009;49:1158-65.
74. Delaney WE 4th, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006;50:2471-7. (Pubitemid 43993188)
75. Boyd A, Lasnier E, Molina JM, et al. Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther 2010;15:963-74.
76. Mallet VO, Dhalluin-Venier V, Verkarre V, et al. Reversibility of cirrhosis in HIV/HBV coinfection. Antivir Ther 2007;12:279-83. (Pubitemid 46569914)
77. Ibrahim F, Naftalin C, Cheserem E, et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS 2010;24:2239-44.
78. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008;48:1062-9.
79. Audsley J, Arrifin N, Yuen LK, et al. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. HIV Med 2009;10:229-35.
80. Boyd A, girard PM, Lacombe K. Consequences of persistent HBV infection in HIV: the double-edged sworf of nucleos(t)ide analogs. Future Virol 2012;7(2):139-48.
81. Ratcliffe L, Beadsworth MB, Pennell A, et al. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 2011;25:1051-6.
82. Maylin S, Boyd A, Lavocat F, et al. Kinetics of HBs and HBe antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-HBV infected patients. AIDS Published Online First: 13 February 2012. doi:10.1097/QAD.0b013e328352224d
83. Moreno S, Garcia-Samaniego J, Moreno A, et al. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat 2009;16:249-58.
84. Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009;16:300-14.
85. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997;350:1425-31. (Pubitemid 28036863)
86. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9. (Pubitemid 38988594)
87. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50. (Pubitemid 38988593)
88. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48. (Pubitemid 39628231)
89. Nunez M, Miralles C, Berdun MA, et al PRESCO Study Group. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972-82. (Pubitemid 47492337)
90. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009;49:22-31.
91. Dietrich DT, Soriano V, Sherman KE, et al. Telaprevir in Combination with Peginterferon Alfa-2A/Ribavirin in HCV/HIV co-infected patients; SVR12 interim analysis. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA, 2011, (abstract 46).
92. Sulkowski M, Pol S, Cooper C, et al. Boceprevir plus Peginterferon/ ribavirin for the treatment of HCV/HIV co-infected patients. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA, 2011, (abstract 47).
93. Soriano V, Sherman KE, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS 2011;25:2197-208.
94. Medrano J, Neukam K, Rallon N, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010;51:1209-16.
95. Van Heeswijk RV, Boogaerts G, De Paepe E, et al. Pharmacokenetic Interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. 18th conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, February 27-March 2, 2011, (abstract 119).
96. Kaserra C, Hughes E, Treitel M, et al. Clinical pharmacology of BOC: metabolism, excretion and drug-drug interactions. 18th conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, February 27-March 2, 2011 (abstract 118).
97. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008;47:36-49. (Pubitemid 351619367)
98. Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009;50:1056-63.
99. Pineda JA, Aguilar-Guisado M, Rivero A, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009;49:1274-82.
100. Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010;138:159-64.
101. Moreno A, Cervera C, Fortun J, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis c virus-coinfected liver transplant recipients: a FIPSE/GESIDA Prospective Cohort Study. Liver Transpl 2012;18:70-81.
102. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003;188:1412-20. (Pubitemid 37523925)
103. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transpl 2008;8:355-65.
104. Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation 2008;85:359-68. (Pubitemid 351322759)
105. Antonini TM, Sebagh M, Roque-Afonso AM, et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patientsdusefulness of early markers after liver transplantation. Am J Transpl 2011;11:1686-95.
106. Tateo M, Roque-Afonso AM, Antonini TM, et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009;23:1069-76.
107. Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007;46:941-52. (Pubitemid 47548643)
108. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transpl 2007;7:2816-20. (Pubitemid 350045781)
109. Jain AK, Venkataramanan R, Shapiro R, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002;8:841-5. (Pubitemid 35012297)
110. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004;10:939-44. (Pubitemid 38979268)
111. Puoti M, Rossotti R, Garlaschelli A, et al. Hepatocellular carcinoma in HIV hepatitis C virus. Curr Opin HIV AIDS 2011;6:534-8.
112. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol 2009;21:445-54.
113. Chelis L, Ntinos N, Souftas V, et al. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co-infected patient: possible synergy with HAART? A case report. Med Oncol 2011;28(Suppl 1):S165-8.
114. Perboni G, Costa P, Fibbia GC, et al. Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report. Oncologist 2010;15:142-5.
115. Ozenne V, Gervais A, Peytavin G, et al. Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report. Hepatogastroenterology 2011;58:161-2.
116. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-83.
117. Hainaut P, Boyle P. Curbing the liver cancer epidemic in Africa. Lancet 2008;371:367-8. (Pubitemid 351173307)
118. Wiersma ST, McMahon B, Pawlotsky JM, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011;31:755-61.